Associate Professor David Preiss
|Tel||+44 (0)1865 743527|
PhD FRCPath MRCP
- Honorary Consultant in Metabolic Medicine
MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit
David Preiss studied medicine at the University of Pretoria, South Africa, and qualified as a consultant in Chemical Pathology and Metabolic Medicine in 2012. He was appointed as a Senior Clinical Research Fellow at CTSU in September 2015. He completed his thesis, examining the links between glycaemia and cardiovascular disease, in 2011/2012 and was awarded the University of Glasgow’s Bellahouston Medal for this research. He was recipient of a Rising Star Fellowship from the European Foundation for the Study of Diabetes in 2013, and was also awarded the Royal College of Pathology’s Research Medal for Clinical Biochemistry in 2010.
His major interest is the prevention of cardiovascular disease with particular focus on lipid modification and diabetes. His current research combines clinical trials, epidemiological studies and meta-analyses of major studies. He is Chief Investigator for the NIHR funded LENS trial, a major streamlined study which is investigating the effect of the cholesterol-lowering drug, fenofibrate, on the progression of diabetic eye disease.
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Sattar N. et al, (2016), The Lancet Diabetes & Endocrinology
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.
Preiss D. et al, (2015), Eur Heart J, 36, 1536 - 1546
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Swerdlow DI. et al, (2015), Lancet, 385, 351 - 361
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial
Preiss D. et al, (2014), The Lancet Diabetes and Endocrinology, 2, 116 - 124
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
Preiss D. et al, (2011), JAMA, 305, 2556 - 2564
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.
Preiss D. et al, (2012), JAMA, 308, 804 - 811
Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R. et al, (2016), Lancet, 388, 2532 - 2561
Cholesterol- and blood pressure-lowering drug use for secondary cardiovascular prevention in 2004 - 2013 Europe
Mihaylova BN. et al, (2016), European Journal of Preventive Cardiology
Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.
Rankin NJ. et al, (2016), Int J Epidemiol, 45, 1351 - 1371
Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes.
White J. et al, (2016), JAMA cardiology
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Sattar N. et al, (2016), Diabetologia, 59, 1333 - 1339